Xbrane Biopharma Q3 loss narrows 51% to SEK 11.7 million; Q3 revenue rises to SEK 54.8 million

• Xbrane Biopharma’s third-quarter 2026 loss narrowed 51% year over year to SEK 11.7 million.
• Revenue rose to SEK 54.8 million, including SEK 54.6 million from Ximluci product sales.
• Quarter-end cash and cash equivalents fell 60% year over year to SEK 37.4 million.
• The ranibizumab biosimilar candidate received FDA approval on October 27; partners will work toward a rapid US launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xbrane Biopharma AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.